TB-500 Reconstitution

How to reconstitute TB-500

1. Swab the rubber stopper of the TB-500 vial and the bacteriostatic water vial with an alcohol wipe.
2. Draw 2 ml of bacteriostatic water into a syringe.
3. Inject it slowly down the inside wall of the TB-500 vial, not directly onto the powder.
4. Swirl gently until the powder fully dissolves. Do not shake. Shaking can damage the peptide.
5. Keep the lyophilised powder at 2 to 8 degrees C, or at -20 degrees C for extended storage.

TB-500 concentration by water volume

TB-500 is commonly supplied in 10 mg vials. The concentration depends only on how much bacteriostatic water you add. More water lowers the concentration and makes small doses easier to measure.

TB-500 units to draw

At 5,000 mcg/ml (a 10 mg vial in 2 ml of bacteriostatic water), here is the draw for doses across the range TB-500 is typically used at. Change any number in the calculator above for your own vial.

TB-500 dosing

There is no clinically established dose. Community protocols commonly cite around 2 to 2.5 mg twice weekly during an initial loading phase, then less frequent maintenance dosing, all by subcutaneous injection. These figures come from anecdote and animal extrapolation rather than dose-finding trials, so they should be read as what people report doing, not as a validated protocol. Enter your own vial size, water volume, and target dose in the calculator above to convert any TB-500 protocol into exact insulin-syringe units. For the full profile, see the TB-500 compound page.

Storing reconstituted TB-500

Keep the lyophilised powder at 2 to 8 degrees C, or at -20 degrees C for extended storage. Once mixed with bacteriostatic water, refrigerate and use within about 28 to 30 days on preservative grounds rather than from any stability study. Protect from light and avoid repeated freeze-thaw.

TB-500 is not thymosin beta-4. It is a synthetic 7-amino-acid fragment (Ac-LKKTETQ, residues 17 to 23), while thymosin beta-4 is the full 43-amino-acid protein, and human trial data on the full protein does not transfer to the fragment. The FDA placed the LKKTETQ fragment in Category 2 of the 503A bulks list in September 2023, barring it from compounding. It is also prohibited by WADA at all times. No human pharmacokinetic or dose-ranging study of the fragment has been published, so the range above is community protocol.

There is no approved human dose for TB-500. The range above reflects preclinical work and community protocols, not dose-finding trials, which is a meaningful distinction.

The math

• Concentration (mcg/ml) = vial size in mg × 1,000 ÷ bacteriostatic water in ml.
• Volume for your dose (ml) = dose in mcg ÷ concentration.
• Units to draw = volume in ml × 100 on a U-100 insulin syringe.

Prefer a full workspace? The peptide dosage & reconstitution calculator adds blend, converter, half-life, and titration tools.

TB-500 reconstitution FAQ

References

• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• https://www.wada-ama.org/en/prohibited-list